Press Releases

Ocular Therapeutix™ to Present at the 2019 Wells Fargo Healthcare Conference
arrow
August 29, 2019
Ocular Therapeutix™ Reports Second Quarter 2019 Financial Results and Business Update
arrow
August 07, 2019
Ocular Therapeutix™ To Report Second Quarter 2019 Financial Results
arrow
August 01, 2019
Ocular Therapeutix™ Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services
arrow
July 26, 2019
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
arrow
July 11, 2019
Ocular Therapeutix™ Announces Christopher White as Senior Vice President, Head of Business and Corporate Development
arrow
July 11, 2019
Ocular Therapeutix™ Announces Patricia Kitchen as Chief Operations Officer
arrow
July 09, 2019
Ocular Therapeutix™ Announces Commercial Launch of DEXTENZA® (dexamethasone intracanalicular insert) 0.4 mg for Ophthalmic Use in the United States
arrow
July 01, 2019
Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
arrow
June 21, 2019
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
arrow
May 30, 2019
Ocular Therapeutix™ Announces Receipt of C-Code and Pass-Through Payment Status for DEXTENZA®
arrow
May 29, 2019
Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma
arrow
May 20, 2019
Ocular Therapeutix™ Reports First Quarter 2019 Financial Results and Business Update
arrow
May 10, 2019
Ocular Therapeutix™ To Report First Quarter 2019 Financial Results
arrow
May 02, 2019
Ocular Therapeutix Announces DEXTENZA® (dexamethasone ophthalmic insert) Recommended for Unique J-Code by CMS
arrow
May 01, 2019
Ocular Therapeutix, Inc. Settles Litigation with Mati Therapeutics, Inc.
arrow
April 30, 2019
Ocular Therapeutix™ to Present New Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
arrow
April 24, 2019
Ocular Therapeutix™ Reports Changes to Board of Directors
arrow
April 23, 2019
Ocular Therapeutix™ to Present at the H.C. Wainwright Global Life Sciences Conference
arrow
April 03, 2019
Ocular Therapeutix™ Announces Notification of FDA Acceptance of Supplemental New Drug Submission for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
arrow
April 02, 2019
Ocular Therapeutix™ Reports Election of Leslie Williams to Board of Directors
arrow
March 25, 2019
Ocular Therapeutix™ to Host 2019 Research & Development Day
arrow
March 21, 2019
Ocular Therapeutix™ Reports Fourth Quarter and Year End 2018 Financial Results and Business Update
arrow
March 07, 2019
Ocular Therapeutix™ to Present at the Cowen and Company 39th Annual Health Care Conference
arrow
March 05, 2019
Ocular Therapeutix™ To Report Fourth Quarter and Year End 2018 Financial Results
arrow
March 01, 2019
Ocular Therapeutix™ Prices $37.5 Million Subordinated Convertible Debt Financing
arrow
February 21, 2019
Ocular Therapeutix™ Announces Dosing of First Patient in OTX-TKI (tyrosine kinase inhibitor implant) Phase 1 Clinical Trial for the Treatment of Wet Age-related Macular Degeneration (AMD)
arrow
February 20, 2019
Ocular Therapeutix™ Submits Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
arrow
January 10, 2019
Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain
arrow
January 07, 2019